Abstract:Background: Homologous recombination deficiency (HRD) is the hallmark of breast cancer gene 1/2 (BRCA1/2)-mutated tumors and the unique biomarker for predicting response to double-strand break (DSB)-inducing drugs. The demonstration of HRD in tumors with mutations in genes other than BRCA1/2 is considered the best biomarker of potential response to these DSB-inducer drugs. Objectives: We explored the potential of developing a practical approach to predict in any tumor the presence of HRD that is similar to that seen in tumors with BRCA1/2 mutations using next-generation sequencing (NGS) along with machine learning (ML). Design: We use copy number alteration (CNA) generated from routine-targeted NGS data along with a modified naïve Bayesian model for the prediction of the presence of HRD. Methods: The CNA from NGS of 434 targeted genes was analyzed using CNVkit software to calculate the log2 of CNA changes. The log2 values of various sequencing reads (bins) were used in ML to train the system on predicting tumors with BRCA1/2 mutations and tumors with abnormalities similar to those detected in BRCA1/2 mutations. Results: Using 31 breast or ovarian cancers with BRCA1/2 mutations and 84 tumors without mutations in any of 12 homologous recombination repair (HRR) genes, the ML demonstrated high sensitivity (90%, 95% confidence interval [CI] = 73%-97.5%) and specificity (98%, 95% CI = 90%-100%). Testing of 114 tumors with mutations in HRR genes other than BRCA1/2 showed 39% positivity for HRD similar to that seen in BRCA1/2. Testing 213 additional wild-type (WT) cancers showed HRD positivity similar to BRCA1/2 in 32% of cases. Correlation with proportional loss of heterozygosity (LOH) as determined using whole exome sequencing of 51 samples showed 90% (95% CI = 72%-97%) concordance. The approach was also validated in an independent set of 1312 consecutive tumor samples. Conclusions: These data demonstrate that CNA when combined with ML can reliably predict the presence of BRCA1/2 level HRD with high specificity. Using BRCA1/2 mutant cases as gold standard, this ML can be used to predict HRD in cancers with mutations in other HRR genes as well as in WT tumors.

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants

BRCA1-specific machine learning model predicts variant pathogenicity with high accuracy

Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2

Leveraging cancer mutation data to predict the pathogenicity of germline missense variants

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

AI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes

Homologous Recombination Abnormalities Associated With BRCA1/2 Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data

Machine learning model to predict risk assessment of a child inheriting a genetic disorder

Predicting loss-of-function impact of genetic mutations: a machine learning approach

Using Machine Learning and Natural Language Processing to Review and Classify the Medical Literature on Cancer Susceptibility Genes

Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity

Classification of genetic variants using machine learning

Improved Detection of Rare Genetic Variants for Diseases

Real-world evaluation of deep learning algorithms to classify functional pathogenic germline variants

Prioritizing Genomic Variants Pathogenicity Via DNA, RNA, and Protein-Level Features Based on Extreme Gradient Boosting

VariPred: Enhancing Pathogenicity Prediction of Missense Variants Using Protein Language Models

Gene Association Study with SVM,MLP and Cross-Validation for the Diagnosis of Diseases

When Two plus Four Does Not Equal Six: Combining Computational and Functional Evidence Towards Classification of BRCA1 Key Domain Missense Substitutions.

Prioritisation of Candidate Single Amino Acid Polymorphisms Using One-Class Learning Machines.

Evaluation of for variant classification in missense variants of solid cancer with actionable genetic targets